Navigation menu


A systematic review and meta-analysis". West J Emerg Med. Archived PDF from the original on September 22, It is extremely important to optimize the medications that are used for these problems to assure they are not causing a gain or failure to lose weight. Our aim is to diminish the burden of chronic disease in the individual affected by Obesity.

Weight Loss


Metformin has been suggested as increasing production of lactate in the large intestine, which could potentially contribute to lactic acidosis in those with risk factors.

Lactic acidosis is initially treated with sodium bicarbonate , although high doses are not recommended, as this may increase intracellular acidosis. A review of metformin overdoses reported to poison control centers over a five-year period found serious adverse events were rare, though the elderly appeared to be at greater risk. The most common symptoms following overdose include vomiting, diarrhea , abdominal pain, tachycardia , drowsiness, and, rarely, hypoglycemia or hyperglycemia.

Extracorporeal treatments are recommended in severe overdoses. Metformin may be quantified in blood, plasma, or serum to monitor therapy, confirm a diagnosis of poisoning, or assist in a forensic death investigation. Chromatographic techniques are commonly employed. The H 2 -receptor antagonist cimetidine causes an increase in the plasma concentration of metformin by reducing clearance of metformin by the kidneys; [91] both metformin and cimetidine are cleared from the body by tubular secretion , and both, particularly the cationic positively charged form of cimetidine, may compete for the same transport mechanism.

Metformin also interacts with anticholinergic medications, due to their effect on gastric motility. Anticholinergic drugs reduce gastric motility, prolonging the time drugs spend in the gastrointestinal tract. This impairment may lead to more metformin being absorbed than without the presence of an anticholinergic drug, thereby increasing the concentration of metformin in the plasma and increasing the risk for adverse effects.

Metformin's main effect is to decrease liver glucose production. Metformin decreases high blood sugar , primarily by suppressing liver glucose production hepatic gluconeogenesis.

Multiple potential mechanisms of action have been proposed, including; inhibition of the mitochondrial respiratory chain complex I , activation of AMP-activated protein kinase AMPK , inhibition of glucagon-induced elevation of cyclic adenosine monophosphate cAMP with reduced activation of protein kinase A PKA , inhibition of mitochondrial glycerophosphate dehydrogenase , and an effect on gut microbiota.

Activation of AMPK was required for metformin's inhibitory effect on liver glucose production. In addition to suppressing hepatic glucose production, metformin increases insulin sensitivity, enhances peripheral glucose uptake by inducing the phosphorylation of GLUT4 enhancer factor , decreases insulin-induced suppression of fatty acid oxidation , [] and decreases absorption of glucose from the gastrointestinal tract.

Increased peripheral use of glucose may be due to improved insulin binding to insulin receptors. AMPK probably also plays a role in increased peripheral insulin sensitivity, as metformin administration increases AMPK activity in skeletal muscle. The usual synthesis of metformin, originally described in , involves the one-pot reaction of dimethylamine hydrochloride and 2-cyanoguanidine over heat.

According to the procedure described in the Aron patent, [] and the Pharmaceutical Manufacturing Encyclopedia , [] equimolar amounts of dimethylamine and 2-cyanoguanidine are dissolved in toluene with cooling to make a concentrated solution, and an equimolar amount of hydrogen chloride is slowly added. Steady state is usually reached in one or two days. Metformin has acid dissociation constant values pKa of 2. The metformin pKa values make metformin a stronger base than most other basic medications with less than 0.

Furthermore, the lipid solubility of the nonionized species is slight as shown by its low logP value log 10 of the distribution coefficient of the nonionized form between octanol and water of These chemical parameters indicate low lipophilicity and, consequently, rapid passive diffusion of metformin through cell membranes is unlikely. As a result of its low lipid solubility it requires the transporter SLC22A1 in order for it to enter cells.

More lipophilic derivatives of metformin are presently under investigation with the aim of producing prodrugs with superior oral absorption than metformin. Metformin is not metabolized. It is cleared from the body by tubular secretion and excreted unchanged in the urine; metformin is undetectable in blood plasma within 24 hours of a single oral dose.

The biguanide class of antidiabetic medications, which also includes the withdrawn agents phenformin and buformin , originates from the French lilac or goat's rue Galega officinalis , a plant used in folk medicine for several centuries.

Metformin was first described in the scientific literature in , by Emil Werner and James Bell, as a product in the synthesis of N , N -dimethylguanidine. Interest in metformin resumed at the end of the s. In , metformin, unlike some other similar compounds, was found not to decrease blood pressure and heart rate in animals.

Garcia [] used metformin he named it Fluamine to treat influenza; he noted the medication "lowered the blood sugar to minimum physiological limit" and was not toxic.

Garcia believed metformin to have bacteriostatic , antiviral , antimalarial , antipyretic and analgesic actions. Instead he observed antiviral effects in humans.

French diabetologist Jean Sterne studied the antihyperglycemic properties of galegine , an alkaloid isolated from Galega officinalis , which is related in structure to metformin and had seen brief use as an antidiabetic before the synthalins were developed. Sterne was the first to try metformin on humans for the treatment of diabetes; he coined the name "Glucophage" glucose eater for the medication and published his results in Metformin became available in the British National Formulary in It was sold in the UK by a small Aron subsidiary called Rona.

Broad interest in metformin was not rekindled until the withdrawal of the other biguanides in the s. Metformin was approved in Canada in , [] but did not receive approval by the U.

Liquid metformin is sold under the name Riomet in India. Metformin IR immediate release is available in , , and mg tablets. All of these are available as generic medications in the U. Metformin SR slow release or XR extended release was introduced in It is available in , , and mg strengths, mainly to counteract common gastrointestinal side effects, as well as to increase compliance by reducing pill burden. No difference in effectiveness exists between the two preparations.

When used for type 2 diabetes, metformin is often prescribed in combination with other medications. Several are available as fixed-dose combinations , to reduce pill burden and simplify administration. A combination of metformin and rosiglitazone was released in and sold as Avandamet by GlaxoSmithKline. By it had become the most popular metformin combination.

In , the stock of Avandamet was removed from the market, after inspections showed the factory where it was produced was violating good manufacturing practices. However, following a meta-analysis in that linked the medication's use to an increased risk of heart attack , [] concerns were raised over the safety of medicines containing rosiglitazone. In September the European Medicines Agency EMA recommended that the medication be suspended from the European market because the benefits of rosiglitazone no longer outweighed the risks.

In November , the FDA lifted its earlier restrictions on rosiglitazone after reviewing the results of the RECORD clinical trial a six-year, open label randomized control trial , which failed to show elevated risk of heart attack or death associated with the medication.

Dipeptidyl peptidase-4 inhibitors inhibit dipeptidyl peptidase-4 and thus reduce glucagon and blood glucose levels. In Europe, Canada, and elsewhere metformin combined with linagliptin is marketed under the trade name Jentadueto.

Sulfonylureas act by increasing insulin release from the beta cells in the pancreas. Metformin is available combined with the sulfonylureas glipizide Metaglip and glibenclamide US: Meglitinides are similar to sulfonylureas.

The combination of metformin with pioglitazone and glibenclamide [] is available in India as Triformin. From Wikipedia, the free encyclopedia. B No risk in non-human studies. S4 Prescription only CA: Pharmacy and pharmacology portal Medicine portal. Clinical Pharmacology and Therapeutics. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus". Archived from the original on 24 December Retrieved 2 January A Systematic Review and Meta-analysis".

Annals of Internal Medicine. Archived from the original on Archived PDF from the original on First choice for monotherapy: Analogue-based Drug Discovery II.

Herb, nutrient, and drug interactions: Archived PDF from the original on 13 December Retrieved 8 December Archived from the original on 3 August Retrieved 11 January Blake; Stanifer, John W.

Diab Vasc Dis Res. International Journal of Obesity. The Cochrane Database of Systematic Reviews. Current Medical Diagnosis and Treatment 49th ed. Bristol-Myers Squibb Company; N Engl J Med.

Annals of the New York Academy of Sciences. Royal College of Obstetricians and Gynaecologists. Scientific Advisory Committee Opinion Paper Archived from the original PDF on European Journal of Endocrinology.

Acta Obstetricia et Gynecologica Scandinavica. Journal of Human Reproductive Sciences. Diabetes research and clinical practice. A Systematic Review and Meta-Analysis". The Scientific World Journal. British Journal of Clinical Pharmacology. When you see a board certified Obesity Medicine Specialist at Inland Empire Weight Loss, besides all of the items listed to the left under Weight Watchers, look at how our weight loss program stacks up to Nutrisystem:.

Getting kids to lose weight is very different than getting adults to lose weight. First of all, obesity in kids is measured differently than it is in adults. Kids get insulin resistance and diabetes just like adults but the laboratory findings are different and they need to be assessed by a health care provider trained in this area. We stress that there needs to be changes in the whole family when it comes to things such as eating and exercise.

We help to properly assess your child in a sensitive way for problematic weight and weight related health programs and then we will propose a program that your child will be excited about participating in. If you are worried that your child has a problem with their weight or if they have been told to lose weight by their pediatrician, then we are here to help.

Obesity Medicine is new specialty that is governed and credentialed through the American Board of Obesity Medicine. Organizations that provide educational support and recognition to the field of Obesity Medicine can be found here. An Obesity Medicine trained physician will not only help you to lose weight but will be an expert in recognizing and treating your weight related conditions. This is important because as you lose weight, your medications that you have been taking for your weight related condition will frequently change.

You can prefill this out or review it at home to understand the risks and benefits to the weight loss process. This packet is used for our non-weight loss patients. Please come to your appointment with this filled out to speed up the check in process. If you are having trouble opening the forms, you may need to download and install Adobe Acrobat Reader. Just click here and you will be taken to a page where you can download Adobe Acrobat Reader.

If you are a Human Resources manager or a corporate executive who is looking to lower health care costs within your organization by reducing the chronic disease burden among your employees, then Inland Empire Weight Loss would like to help. We offer a wellness program designed to reduce and improve obesity related chronic conditions through improvements in lifestyle, diet, and exercise. If your company offers a shared or full risk environment in providing health care benefits to your employees, then a wellness program such as ours will offer immediate benefits in reducing healthcare pharmacy, medical, and hospital claims.

Additionally, if your employees have a reduced weight and improvements in their health, there will be a decrease in absenteeism and an increase in productivity. Knopke is double board certified in Obesity Medicine and Family Medicine.

He is a leader in the field of Obesity Medicine. Additionally he is a member of many other related Medical Associations. He has spoken to and taught other medical professionals both locally and nationally on topics related to Obesity Medicine. He also offers a 4th year elective rotation to UCR medical students interested in pursuing a career in the field of Obesity Medicine.

He is an active participant in designing continuing medical education CME programs on the topic of obesity medicine through OMA. Further information on Dr. Knopke can be found on his LinkedIn page. Interested parties are invited to send an email to Dr. Knopke at drknopke inlandempireweightloss. Knopke about options for the corporate program.

Knopke can meet individually with HR managers or other corporate decision makers on a one on one basis to discuss options should there be interest in our program. We look forward to making your employees healthier. One of the big advantages of choosing a clinic that is run by a board certified Obesity Medicine Specialist is that we can take care of a wide spectrum of medical needs.

Whether you have recently gained pounds through a pregnancy and you have not been able to lose the weight or you are currently taking multiple medications to treat chronic health conditions such as diabetes or hypertension, we are here to help. We even see people after bariatric surgery who have plateaued in their weight loss.

Read about our pricing structure below and decide which program is best for you. If you are cost sensitive, please let your healthcare provider know so that we can shape a program that is right for you.

Our least expensive option is our Basic program with an added supply of phentermine to make it last for a month. You will not find a better price in the Inland Empire. Please see our specials page for our current offers. For your convenience, we also accept CareCredit. This is our best value. It is intended for the person who has recently gained weight and has not able to lose it on their own. Carrying extra weight over many years exposes you to multiple health risks. This is especially so if you have someone in your family with weight related health problems.

Allow us to evaluate you for your health risks and let us show you how to lose the weight and feel great. This is our most popular level. We find that many of our patients have struggled to lose weight even with an appetite suppressant. Often we see patients from other weight loss clinics who were told to stop taking their appetite suppressent when they stopped losing weight.

We see things differently. The appetite suppressant is a tool to achieve a result but it is not the only tool we have! There are many ways to break through a plateau. This is what we do! This is where we really shine. If you have several health problems and you are taking multiple medications, we can help.

Do you have diabetes and you are on insulin? We can get your blood sugar down and take you off of your insulin. Have the costs of your medications become too much? Have you already had bariatric surgery and you have stopped losing weight? We can help you. If you have a fee-for-service type health insurance and multiple medical problems, then this is the best option for you. Did you know that most of the listed insurance plans have at least some coverage for weight loss?

Let us evaluate you for your qualifications to use your health insurance. We can usually find a way to make it work. Each visit comes with a 2-week supply. Extend this out to a month for only a little more. Getting an EKG as a component of your initial evaluation can be important to help identify cardiac issues that may put you at risk.

We do recommend that you get this prior to starting on the program. These are our most popular injection. Each comes with a mixture of vitamins designed to mobilize fat stores and increase energy levels.

Try these at other centers and they can be painful on injection. Our proprietary formula is designed to minimize the discomfort that is associated with this formulation. Many people lack the ability to absorb vitamin B12 or they take medications which makes absorption difficult.

Others like the effect of a little extra B12 in their system and feel a boost of energy. Ask us about this and we can tell you if this is right for you. For many of our patients, this is the "secret formula" to their success. We carry a wide range of products ranging from soups, bars, shakes, and meat sticks.

All are formulated to provide you with an increased supply of protein and low delivery of carbohydrates. If you have particular needs in your meal replacements, just ask us and we can help you to decide if this option is right for you. We find that many of our patients, both men and women, suffer from hormone related problems as a consequence of their excess weight.

Like many problems we see related to obesity, unhealthy hormone levels are both a consequence and a cause of weight problems. Often, by subtle alterations of your hormones, we can enable weight loss where you have struggled before.

Ask us how this can help you. Addressing additional problems may be limited by time and safety as determined by the provider.

A prescription for an alternative appetite suppressant may be given in lieu of dispensing a medication. Savings with insurance assumes you have satisfied your deductable. Please ask for more details if you have questions. Inland Empire Weight Loss is currently accepting consultation requests in the area of Obesity Medicine. The specialty board of Obesity Medicine was established in Further information on this board can be found here.

Upon request of a consultation, you as a provider will receive a consultation letter from Dr. If there are questions in regards to the plan, Dr.

Knopke will be more than happy to discuss any concerns you may have on the phone. Our aim is to diminish the burden of chronic disease in the individual affected by Obesity. We accept most major PPO health insurances as well as Medicare.

We accept consultations for the following requests:. Knopke is a leader in the field of Obesity Medicine. He is an active participant in designing continuing medical education CME programs on the topic of Obesity Medicine which are designed to educate other Obesity Medicine providers around the country on various topics in Obesity Medicine. He is also an instructor for the OMA for their board preparatory course to help other physicians study for and pass their Obesity Medicine Board exam.

Should you have any questions about the nature of our program, Dr. Knopke can be reached at drknopke inlandempireweightloss. Behavior The cornerstone of any successful weight loss program is behavioral management. Nutrition We use a combination of education and medical grade meal replacements to facilitate weight loss.